NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free GHRS Stock Alerts $10.50 -0.58 (-5.23%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$10.30▼$10.9850-Day Range$7.44▼$11.7252-Week Range$5.05▼$14.64Volume32,083 shsAverage Volume131,936 shsMarket Capitalization$546.32 millionP/E RatioN/ADividend YieldN/APrice Target$39.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GH Research alerts: Email Address GH Research MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside276.2% Upside$39.50 Price TargetShort InterestBearish4.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.96) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector685th out of 908 stocksPharmaceutical Preparations Industry315th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.95% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently increased by 10.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GHRS. Previous Next 2.3 News and Social Media Coverage News SentimentGH Research has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GH Research this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GHRS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.96) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -15.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -15.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About GH Research Stock (NASDAQ:GHRS)GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Read More GHRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GHRS Stock News HeadlinesApril 26, 2024 | bizjournals.comMGB expands effort to make medical research more sustainableApril 26, 2024 | msn.comGH Video Preview: Gregory in Trouble, Joss Tells Jason She Did Something She RegretsApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 20, 2024 | americanbankingnews.comContrasting GH Research (NASDAQ:GHRS) & ORIC Pharmaceuticals (NASDAQ:ORIC)April 18, 2024 | yahoo.comGeneral Hospital Video Preview: Is Cyrus the Key to Bringing Down Sonny?April 17, 2024 | yahoo.comGH Spoilers Weekly Preview Video: It’s Sonny Corinthos Versus the WorldMarch 17, 2024 | yahoo.comGeneral Hospital Video Preview: Misdirections, Maladies, and MisdiagnosesMarch 15, 2024 | yahoo.comGeneral Hospital Video Preview: Catastrophic Thoughts Plague Jason and SonnyApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 15, 2024 | yahoo.comThe General Hospital Coming Out Storyline Nobody Saw ComingMarch 4, 2024 | markets.businessinsider.comBuy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property AdvancesMarch 1, 2024 | markets.businessinsider.comBuy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial HealthMarch 1, 2024 | msn.comGH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business UpdatesFebruary 29, 2024 | globenewswire.comGH Research Reports Full Year 2023 Financial Results and Provides Business UpdatesJanuary 18, 2024 | finance.yahoo.comGH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionJanuary 16, 2024 | finance.yahoo.comCan GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?January 16, 2024 | yahoo.comGeneral Hospital Season 61: How Many Episodes & When Do New Episodes Come Out?December 26, 2023 | yahoo.comGeneral Hospital Season 61 Streaming: Watch & Stream Online via HuluDecember 25, 2023 | finance.yahoo.comWe're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyDecember 20, 2023 | nasdaq.comThese Four Stocks Tap into the Exploding Psychedelic Treatment MarketNovember 24, 2023 | msn.comPsyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And MoreNovember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)November 10, 2023 | markets.businessinsider.comGH Research Earns ‘Buy’ Rating: Promising Progress, Proactive Approach, and Solid Financial StandingNovember 10, 2023 | finanznachrichten.deGH Research PLC: GH Research Reports Third Quarter Financial Results and Provides Business UpdatesNovember 9, 2023 | finance.yahoo.comGH Research Reports Third Quarter Financial Results and Provides Business UpdatesNovember 2, 2023 | morningstar.comGH Research PLC GHRSOctober 3, 2023 | markets.businessinsider.comPositive Outlook for GH Research Despite FDA’s Clinical Hold: An Analysis of GH001’s Trials and ProspectsSee More Headlines Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GHRS CUSIPN/A CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$39.50 High Stock Price Target$40.00 Low Stock Price Target$39.00 Potential Upside/Downside+276.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-15.48% Return on Assets-15.01% Debt Debt-to-Equity RatioN/A Current Ratio24.49 Quick Ratio24.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book2.13Miscellaneous Outstanding Shares52,030,000Free Float30,384,000Market Cap$546.32 million OptionableOptionable Beta0.84 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Florian Schonharting M.Sc. (Econ) (Age 55)Co-Founder & Non-Executive Chairman of the Board Dr. Theis Terwey M.D. (Age 48)Co-Founder & CEO Mr. Magnus Halle (Age 27)Co-Founder & MD of Ireland Ms. Julie Ryan F.C.A. (Age 38)Vice President of Finance Mr. Aaron Cameron M.B.A. (Age 39)Chief Operating Officer Mr. Naoise GaffneyVP & Head of Intellectual PropertyDr. Velichka Valcheva M.D. (Age 49)Chief Medical Officer More ExecutivesKey CompetitorsORIC PharmaceuticalsNASDAQ:ORICNuvation BioNYSE:NUVBCureVacNASDAQ:CVACVerve TherapeuticsNASDAQ:VERVZymeworksNYSE:ZYMEView All CompetitorsInstitutional OwnershipBVF Inc. ILBought 1,125,000 shares on 2/15/2024Ownership: 20.586%Verition Fund Management LLCSold 22,753 shares on 2/14/2024Ownership: 0.000%AdvisorShares Investments LLCBought 1,977 shares on 2/14/2024Ownership: 0.000%View All Institutional Transactions GHRS Stock Analysis - Frequently Asked Questions Should I buy or sell GH Research stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHRS shares. View GHRS analyst ratings or view top-rated stocks. What is GH Research's stock price target for 2024? 2 brokers have issued 12-month price targets for GH Research's stock. Their GHRS share price targets range from $39.00 to $40.00. On average, they predict the company's stock price to reach $39.50 in the next twelve months. This suggests a possible upside of 276.2% from the stock's current price. View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts. How have GHRS shares performed in 2024? GH Research's stock was trading at $5.80 at the beginning of 2024. Since then, GHRS shares have increased by 81.0% and is now trading at $10.50. View the best growth stocks for 2024 here. Are investors shorting GH Research? GH Research saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,450,000 shares, an increase of 10.7% from the March 31st total of 1,310,000 shares. Based on an average trading volume of 127,200 shares, the short-interest ratio is currently 11.4 days. Approximately 5.0% of the company's shares are short sold. View GH Research's Short Interest. When is GH Research's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GHRS earnings forecast. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.01. What ETFs hold GH Research's stock? ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL). When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GHRS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
